Sarepta will halt all shipments of Elevidys, its drug for Duchenne muscular dystrophy patients, by Tuesday evening.

AstraZeneca announced that it will invest $50 billion in the U.S. by 2030, including a multi-billion-dollar manufacturing ...

University of Minnesota president Rebecca Cunningham is drawing on her experience as an emergency physician in this ...

The Food and Drug Administration on Monday named George Tidmarsh, a longtime biotech executive who has a background in ...

The number of basic science papers published by NIH grant recipients has been falling since 2013, when the agency’s budget ...

WASHINGTON — President Trump’s major domestic policy law will result in nearly 10 million more people going without health ...

The crisis over Sarepta Therapeutics' Duchenne therapy offers a valuable lesson: Listening to critics, and responding with ...

CASP, the protein structure prediction contest that launched DeepMind’s Alphafold to international fame and a Nobel Prize, ...

Since the Affordable Care Act went into effect, health insurance companies have been a favorite on Wall Street. More people were gaining health coverage, and the shift toward government programs ...

As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...

Sarepta Therapeutics refused a FDA request to halt shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy ...

On Friday, Congressional Republicans passed legislation to take back money they’d already appropriated this year, enacting steep cuts to foreign aid and public broadcasting. It doesn’t sound like it’s ...